Marta Coscia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8197658/publications.pdf

Version: 2024-02-01

110	3,547	147801	149698
papers	citations	31 h-index	56 g-index

112	112	112	5378
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	1.4	239
2	Zoledronic acid repolarizes tumourâ€associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	3.6	228
3	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	7.2	198
4	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
5	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica, 2013, 98, 953-963.	3.5	195
6	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood, 2015, 125, 111-123.	1.4	151
7	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	127
8	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood, 2011, 118, 6141-6152.	1.4	122
9	Effector Î³Î´ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia, 2005, 19, 664-670.	7.2	119
10	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia, 2014, 28, 1060-1070.	7.2	105
11	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. Journal of Immunology, 2011, 187, 1578-1590.	0.8	77
12	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
13	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.	7.2	63
14	Murine β-defensin 2 promotes TLR-4/MyD88-mediated and NF-κB-dependent atypical death of APCs via activation of TNFR2. Journal of Leukocyte Biology, 2008, 83, 998-1008.	3.3	61
15	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia, 2011, 25, 828-837.	7.2	61
16	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia, 2021, 35, 737-746.	7.2	61
17	Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. OncoImmunology, 2015, 4, e1047580.	4.6	58
18	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 2015, 29, 1360-1365.	7.2	57

#	Article	IF	Citations
19	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
20	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood, 2004, 104, 1961-1969.	1.4	55
21	Dysfunctional VÎ³9VÎ´2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood, 2012, 120, 3271-3279.	1.4	51
22	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. PLoS ONE, 2013, 8, e60975.	2.5	49
23	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 2001, 113, 1051-1059.	2.5	48
24	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Advances, 2016, 1, 47-61.	5.2	48
25	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T?cells. European Journal of Immunology, 2005, 35, 1155-1163.	2.9	45
26	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology, 2020, 11, 888.	4.8	45
27	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. Journal of Clinical Investigation, 2015, 126, 181-194.	8.2	44
28	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica, 2014, 99, 888-896.	3.5	43
29	HIF-1Î± is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
30	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2020, 11, 594556.	4.8	39
31	VÎ³9VÎ´2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cellular and Molecular Life Sciences, 2011, 68, 2419-2432.	5.4	35
32	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia, 2015, 29, 356-368.	7.2	33
33	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget, 2015, 6, 29833-29846.	1.8	33
34	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
35	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood, 2021, 137, 3507-3517.	1.4	30
36	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. Journal of Immunology Research, 2017, 2017, 1-13.	2.2	29

#	Article	IF	Citations
37	Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. Journal of Leukocyte Biology, 2004, 76, 77-85.	3.3	28
38	Cancer immunotherapy with chemoattractant peptides. Seminars in Cancer Biology, 2004, 14, 209-218.	9.6	27
39	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status. Haematologica, 2014, 99, 1605-1610.	3.5	27
40	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. Clinical Cancer Research, 2007, 13, 5348-5354.	7.0	26
41	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richterâ€™s syndrome: therapeutic implications. Leukemia, 2020, 34, 462-477.	7.2	24
42	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica, 2015, 100, e501-e504.	3.5	22
43	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. European Journal of Cancer, 2016, 60, 154-165.	2.8	22
44	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers, 2020, 12, 282.	3.7	22
45	CD200 included in a 4â€marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. Hematological Oncology, 2018, 36, 543-546.	1.7	21
46	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leukemia and Lymphoma, 2014, 55, 841-847.	1.3	17
47	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	7.2	17
48	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. British Journal of Haematology, 2000, 109, 46-53.	2.5	16
49	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-NaÃ¯ve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers, 2019, 11, 896.	3.7	16
50	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 2021, 13, 3240.	3.7	16
51	Venetoclax in CLL patients who progress after Bâ€cell Receptor inhibitor treatment: a retrospective multiâ€centre Italian experience. British Journal of Haematology, 2019, 187, e8-e11.	2.5	14
52	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	5.2	14
53	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	1.7	13
54	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget, 2017, 8, 3274-3288.	1.8	13

#	Article	IF	Citations
55	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. European Journal of Haematology, 2017, 99, 306-314.	2.2	12
56	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
57	Frontline treatment with the combination obinutuzumab Â± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. American Journal of Hematology, 2020, 95, 604-611.	4.1	12
58	Targeting HIF-1Î± Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. Cancers, 2021, 13, 2883.	3.7	12
59	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 3856.	3.7	12
60	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. Frontiers in Bioscience - Landmark, 2019, 24, 1284-1315.	3.0	12
61	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. Blood, 2009, 114, 2333-2333.	1.4	12
62	Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opinion on Biological Therapy, 2004, 4, 959-963.	3.1	11
63	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Experimental Hematology, 2009, 37, 728-738.	0.4	10
64	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. Leukemia and Lymphoma, 2016, 57, 2429-2431.	1.3	10
65	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2021, 137, 2267-2271.	1.4	10
66	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 411-425.	1.8	9
67	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica, 2017, 102, e352-e355.	3.5	9
68	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
69	Predictive value of the <scp>CLL</scp>â€<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemoâ€immunotherapy as firstâ€line treatment. European Journal of Haematology, 2018, 101, 703-706.	2.2	8
70	CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. Leukemia Research, 2019, 83, 106169.	0.8	8
71	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	1.7	8
72	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. Journal of Personalized Medicine, 2021, 11, 249.	2.5	6

#	Article	IF	Citations
73	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. Blood, 2018, 132, 3118-3118.	1.4	6
74	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. Journal of Clinical Medicine, 2022, 11, 2076.	2.4	6
75	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Annals of Hematology, 2020, 99, 2197-2199.	1.8	5
76	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
77	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified threeâ€factor model. American Journal of Hematology, 2022, 97, .	4.1	5
78	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica, 2014, 99, e159-e161.	3.5	4
79	External validation of the accuracy of â€˜CLLflow scoreâ€™. Journal of Investigative Medicine, 2018, 66, e6-e6.	1.6	4
80	Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. Leukemia, 2019, 33, 1030-1051.	7.2	4
81	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers, 2020, 12, 1773.	3.7	4
82	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. Blood, 2020, 136, 21-22.	1.4	4
83	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. Blood, 2020, 136, 25-26.	1.4	3
84	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	3.7	3
85	Editorial: CAR T-Cell Therapies in Hematologic Tumors. Frontiers in Oncology, 2020, 10, 588134.	2.8	2
86	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 4412-4412.	1.4	2
87	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2013, 122, 4177-4177.	1.4	2
88	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	2
89	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
90	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. Blood, 2020, 136, 54-55.	1.4	2

#	Article	IF	Citations
91	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. Blood Advances, 2022, 6, 3875-3878.	5.2	2
92	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term followâ€up. British Journal of Haematology, 2018, 181, 693-695.	2.5	1
93	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica, 2020, 105, 2671-2674.	3.5	1
94	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 4239.	3.7	1
95	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. Blood, 2019, 134, 5485-5485.	1.4	1
96	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
97	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	1.4	1
98	LDH as Predictive Parameter in Treatment-NaÃ¯ve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S213.	0.4	0
99	Regulation of HIF-1 Î± in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S214.	0.4	0
100	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S278-S279.	0.4	0
101	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. Blood, 2011, 118, 2845-2845.	1.4	0
102	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 3881-3881.	1.4	0
103	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). Blood, 2012, 120, 3878-3878.	1.4	0
104	The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1778-1778.	1.4	0
105	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	1.4	0
106	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. Journal of Clinical Oncology, 2018, 36, 7531-7531.	1.6	0
107	Front-Line Treatment with Obinutuzumab Â± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. Blood, 2019, 134, 1766-1766.	1.4	0
108	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. Blood, 2019, 134, 4308-4308.	1.4	0

#	Article	IF	Citations
109	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. Blood, 2020, 136, 23-25.	1.4	0
110	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	1.4	0